The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 1, 2000, Pages 49-56

  Suntharalingam, Mohan ^a   Haas, Michael L ^a   Conley, Barbara A ^a   Egorin, Merrill J ^a   Levy R n, Sharon ^a   Sivasailam, Sankari ^a   Herman M s, Joseph M ^a   Jacobs, Maria C ^a   Gray, William C ^a   Ord, Robert A ^b   Aisner, Joseph A ^c   Van Echo, David A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Carboplatin; Chemoradiation; Head and neck cancer; Paclitaxel; Unresectable

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HEAD AND NECK CARCINOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034176128     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00408-9     Document Type: Article

References (41)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999 [see comments]. CA Cancer J Clin. 49:1999;8-31.
2. Harari P.M. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol. 15:1997;2050-2055.
3. Brizel D.M. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 8:1998;237-246.
4. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer Phase III randomized Intergroup study 0099 . J Clin Oncol. 16:1998;1310-1317.
5. Bourhis J., Eschwege F. Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma Overview of randomized trials . Anticancer Res. 16:1996;2397-2402.
6. Chougule P, Wanebo H, Akerley W; et al. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: A phase II study - preliminary results. Semin Oncol 1997;24:S19-57-S19-61.
7. Espinoza-Jacobs M.C., Suntharalingam M., Eisenberger M., et al. Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck. Am J Clin Oncol. 18:1995;52-55.
8. Haraf D.J., Vokes E.E., Panje W.R., et al. Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 14:1991;419-426.
9. Jacobs M.C., Eisenberger M., Oh M.C., et al. Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck A phase I-II study . Int J Radiat Oncol Biol Phys. 17:1989;361-363.
10. Eisenberger M., Hornedo J., Silva H., et al. Carboplatin (NSC-241-240) An active platinum analog for the treatment of squamous-cell carcinoma of the head and neck . J Clin Oncol. 4:1986;1506-1509.
11. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol) [published erratum appears in N Engl J Med 1995 Jul 6;333:75]. N Engl J Med. 332:1995;1004-1014.
12. Vokes E.E., Weichselbaum R.R., Mick R., et al. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 84:1992;877-882.
13. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [see comments]. N Engl J Med. 338:1998;1798-1804.
14. Vokes E.E., Awan A.M., Weichselbaum R.R. Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol Oncol Clin North Am. 5:1991;753-767.
15. Aisner J., Sinibaldi V., Eisenberger M. Carboplatin in the treatment of squamous cell head and neck cancers. Semin Oncol. 19:1992;60-65.
16. Coughlin C.T., Richmond R.C. Biologic and clinical developments of cisplatin combined with radiation Concepts, utility, projections for new trials, and the emergence of carboplatin . Semin Oncol. 16:1989;31-43.
17. Choy H., Akerley W., DeVore R.F. 3rd. Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol. 26:1999;36-43.
18. Douple E.B., Richmond R.C., O'Hara J.A., et al. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev. 12:(Suppl. A):1985;111-124.
19. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage Prospective evaluation of a simple formula based on renal function [see comments] . J Clin Oncol. 7:1989;1748-1756.
20. Cividalli A., Arcangeli G., Cruciani G., et al. Enhancement of radiation response by paclitaxel in mice according to different treatment schedules. Int J Radiat Oncol Biol Phys. 40:1998;1163-1170.
21. Leonard C.E., Chan D.C., Chou T.C., et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 56:1996;5198-5204.
22. Milas L., Hunter N.R., Mason K.A., et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 55:1995;3564-3568.
23. Pulkkinen J.O., Pekkola-Heino K., Grenman R. Paclitaxel and irradiation induce apoptosis in squamous cell carcinoma cell lines in an additive way. Anticancer Res. 16:1996;2923-2929.
24. Geard C.R., Jones J.M. Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys. 29:1994;565-569.
25. Elomaa L., Joensuu H., Kulmala J., et al. Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol (Stockh). 115:1995;340-344.
26. Conley B, Jacobs M, Suntharalingam M; et al. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Semin Oncol 1997;24:S2-78-S2-80.
27. Suntharalingam M., Sivasailam S., Jacobs M., et al. Weekly paclitaxel/carboplatin and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. Proc ASTRO. 42:1998;322.
28. Glantz M.J., Choy H., Kearns C.M., et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol. 14:1996;600-609.
29. Cockroft D., Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
30. Kaplan E., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 53:1958;457-481.
31. Cox D. Regression models and life-tables (with discussion). J R Stat Soc (B). 34:1972;187-220.
32. El-Sayed S., Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region A meta-analysis of prospective and randomized trials . J Clin Oncol. 14:1996;838-847.
33. Foster B.J., Clagett-Carr K., Leyland-Jones B., et al. Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev. 12:(Suppl. A):1985;43-49.
34. Langer C.J. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol. 9:1999;108-116.
35. Vokes E.E., Haraf D.J., Drinkard L.C., et al. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 35:1995;304-312.
36. Withers H.R., Taylor J.M., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:1988;131-146.
37. Dunphy F, Boyd J, Dunleavy T. Paclitaxel and carboplatin in head and neck cancer. Semin Oncol 1997;24:S19-25-S19-27.
38. Marcial V.A., Pajak T.F., Mohiuddin M., et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck Long-term results of the Radiation Therapy Oncology Group study 81-17 . Cancer. 66:1990;1861-1868.
39. Laramore G.E., Scott C.B., al-Sarraf M., et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck Report on Intergroup Study 0034 [see comments] . Int J Radiat Oncol Biol Phys. 23:1992;705-713.
40. Vokes E.E., Haraf D.J., Mick R., et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer [see comments]. J Clin Oncol. 12:1994;2351-2359.
41. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas Preliminary results of RTOG 9003 . Proc ASTRO. 45:1999;145.